Cargando…
Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?
Pelvic Melanoma relapse occurs in 15% of patients with loco regional metastases, and 25% of cases do not respond to new target-therapy and/or immunotherapy. Melphalan hypoxic pelvic perfusion may, therefore, be an option for these non-responsive patients. Overall median survival time (MST), stratifi...
Autores principales: | Guadagni, Stefano, Fiorentini, Giammaria, Clementi, Marco, Palumbo, Giancarlo, Palumbo, Paola, Chiominto, Alessandro, Baldoni, Stefano, Masedu, Francesco, Valenti, Marco, Di Tommaso, Ambra, Fabi, Bianca, Aliberti, Camillo, Sarti, Donatella, Guadagni, Veronica, Pellegrini, Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5713351/ https://www.ncbi.nlm.nih.gov/pubmed/29120401 http://dx.doi.org/10.3390/ijms18112382 |
Ejemplares similares
-
MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study
por: Guadagni, Stefano, et al.
Publicado: (2017) -
Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability
por: Guadagni, Stefano, et al.
Publicado: (2017) -
Mitomycin C hypoxic pelvic perfusion for unresectable recurrent rectal cancer: pharmacokinetic comparison of surgical and percutaneous techniques
por: Guadagni, Stefano, et al.
Publicado: (2017) -
Circulating tumour cell liquid biopsy in selecting therapy for recurrent cutaneous melanoma with locoregional pelvic metastases: a pilot study
por: Guadagni, Stefano, et al.
Publicado: (2020) -
Updates of colorectal cancer liver metastases therapy: review on DEBIRI
por: Fiorentini, Giammaria, et al.
Publicado: (2020)